---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-315918"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:33:24.455597+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evommune reports Q3 2025 net loss $12.5M; IPO raised $172.5M, three Phase 2 readouts due in 2026

## Summary
- Completed IPO in Nov 2025 of 10.78M shares at $16.00, raising $172.5M gross proceeds.
- Three Phase 2 data readouts expected in 2026: EVO756 CSU (1H26), EVO756 AD (2H26), EVO301 AD (1H26).
- Q3 2025 revenue $10.0M from Maruho collaboration; zero in prior-year quarter.
- Net loss improved to $12.5M vs $15.9M YoY; cash and investments $76.0M as of Sep 30, 2025.
- R&D expenses increased to $19.6M from $13.3M YoY, reflecting pipeline advancement.

## SEC filing metadata
- accession: 0001193125-25-315918
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/0001193125-25-315918-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312525315918/evmn-20251211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-315918
- JSON: https://secwatch.observer/filing/0001193125-25-315918.json
- Plain text: https://secwatch.observer/filing/0001193125-25-315918.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.